Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial : clinical research : hypertension
Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
7 April 2025
|
| In: |
European heart journal
Year: 2025, Jahrgang: 46, Heft: 14, Pages: 1304-1317 |
| ISSN: | 1522-9645 |
| DOI: | 10.1093/eurheartj/ehae938 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/eurheartj/ehae938
|
| Verfasserangaben: | Michael Böhm, Javed Butler, Andrew Coats, Lucas Lauder, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Martina Brueckmann, Sibylle J. Hauske, Elke Schueler, Christoph Wanner, Subodh Verma, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 192756249X | ||
| 003 | DE-627 | ||
| 005 | 20250605082238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250605s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/eurheartj/ehae938 |2 doi | |
| 035 | |a (DE-627)192756249X | ||
| 035 | |a (DE-599)KXP192756249X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Böhm, Michael |d 1958- |e VerfasserIn |0 (DE-588)1096256169 |0 (DE-627)856690694 |0 (DE-576)467967482 |4 aut | |
| 245 | 1 | 0 | |a Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction |b the EMPEROR-Preserved trial : clinical research : hypertension |c Michael Böhm, Javed Butler, Andrew Coats, Lucas Lauder, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Martina Brueckmann, Sibylle J. Hauske, Elke Schueler, Christoph Wanner, Subodh Verma, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators |
| 264 | 1 | |c 7 April 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 14 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 04. März 2025 | ||
| 500 | |a Gesehen am 05.06.2025 | ||
| 520 | |a Hypertension has a high prevalence in heart failure with preserved ejection fraction (HFpEF), which can be controlled, uncontrolled, or even resistant. The effects of empagliflozin on systolic blood pressure (SBP), time in target range, incidence of hypertensive urgencies, and studied cardiovascular and renal outcomes in different hypertension categories and after treatment with empagliflozin in the EMPEROR-Preserved trial were explored.A total of 5533 patients were studied and the population was separated into resistant (resHTN), uncontrolled (uctrHTN), and controlled (ctrHTN) hypertension. The effect of SBP on outcomes and treatment effects of empagliflozin were explored. Analyses were done with Cox regression analyses adjusted for demographic and clinical confounders and with a mixed model for repeated measures.Empagliflozin reduced SBP in resHTN slightly more than in the other categories in the first weeks, while thereafter there were no significant differences. The modest reduction in SBP resulted in a moderate increase in time at target and reduced hypertensive urgencies. The primary endpoint was more prevalent in resHTN (P = .0358), but the treatment effect of empagliflozin on the primary endpoint was similar in resHTN, uctrHTN, and ctrHTN (P for interaction = .92) as was the improvement of the estimated glomerular filtration rate slope (P for interaction = .95) and change in quality of life by empagliflozin.In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories. This indicates that in HFpEF, moderate modifications of blood pressure do not affect overall outcomes and treatment effects of empagliflozin. | ||
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Coats, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lauder, Lucas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahfoud, Felix |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart J |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Hauske, Sibylle J. |d 1976-2025 |e VerfasserIn |0 (DE-588)137856253 |0 (DE-627)596151527 |0 (DE-576)305349686 |4 aut | |
| 700 | 1 | |a Schueler, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wanner, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verma, Subodh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European heart journal |d Oxford : Oxford University Press, 1980 |g 46(2025), 14 vom: Apr., Seite 1304-1317 |h Online-Ressource |w (DE-627)320415813 |w (DE-600)2001908-7 |w (DE-576)103746846 |x 1522-9645 |7 nnas |a Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction the EMPEROR-Preserved trial : clinical research : hypertension |
| 773 | 1 | 8 | |g volume:46 |g year:2025 |g number:14 |g month:04 |g pages:1304-1317 |g extent:14 |a Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction the EMPEROR-Preserved trial : clinical research : hypertension |
| 856 | 4 | 0 | |u https://doi.org/10.1093/eurheartj/ehae938 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250605 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 137856253 |a Hauske, Sibylle J. |m 137856253:Hauske, Sibylle J. |d 60000 |d 61400 |e 60000PH137856253 |e 61400PH137856253 |k 0/60000/ |k 1/60000/61400/ |p 10 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 9 | ||
| 999 | |a KXP-PPN192756249X |e 4731238382 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction","subtitle":"the EMPEROR-Preserved trial : clinical research : hypertension","title":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction"}],"language":["eng"],"name":{"displayForm":["Michael Böhm, Javed Butler, Andrew Coats, Lucas Lauder, Felix Mahfoud, Gerasimos Filippatos, João Pedro Ferreira, Stuart J. Pocock, Martina Brueckmann, Sibylle J. Hauske, Elke Schueler, Christoph Wanner, Subodh Verma, Faiez Zannad, Milton Packer, and Stefan D. Anker, on behalf of the EMPEROR-Preserved Trial Committees and Investigators"]},"person":[{"family":"Böhm","role":"aut","given":"Michael","display":"Böhm, Michael"},{"given":"Javed","role":"aut","display":"Butler, Javed","family":"Butler"},{"family":"Coats","given":"Andrew","role":"aut","display":"Coats, Andrew"},{"family":"Lauder","role":"aut","given":"Lucas","display":"Lauder, Lucas"},{"family":"Mahfoud","display":"Mahfoud, Felix","given":"Felix","role":"aut"},{"display":"Filippatos, Gerasimos","given":"Gerasimos","role":"aut","family":"Filippatos"},{"family":"Ferreira","display":"Ferreira, João Pedro","given":"João Pedro","role":"aut"},{"family":"Pocock","display":"Pocock, Stuart J","given":"Stuart J","role":"aut"},{"family":"Brückmann","display":"Brückmann, Martina","role":"aut","given":"Martina"},{"family":"Hauske","display":"Hauske, Sibylle J.","role":"aut","given":"Sibylle J."},{"family":"Schueler","given":"Elke","role":"aut","display":"Schueler, Elke"},{"family":"Wanner","display":"Wanner, Christoph","role":"aut","given":"Christoph"},{"role":"aut","given":"Subodh","display":"Verma, Subodh","family":"Verma"},{"given":"Faiez","role":"aut","display":"Zannad, Faiez","family":"Zannad"},{"display":"Packer, Milton","given":"Milton","role":"aut","family":"Packer"},{"display":"Anker, Stefan D","given":"Stefan D","role":"aut","family":"Anker"}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"7 April 2025"}],"recId":"192756249X","type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"noteIll":"Diagramme","extent":"14 S."}],"id":{"eki":["192756249X"],"doi":["10.1093/eurheartj/ehae938"]},"note":["Online veröffentlicht: 04. März 2025","Gesehen am 05.06.2025"],"relHost":[{"language":["eng"],"part":{"issue":"14","extent":"14","pages":"1304-1317","volume":"46","year":"2025","text":"46(2025), 14 vom: Apr., Seite 1304-1317"},"title":[{"title":"European heart journal","title_sort":"European heart journal"}],"pubHistory":["1.1980 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"320415813","origin":[{"dateIssuedKey":"1980","publisher":"Oxford University Press ; Harcourt","dateIssuedDisp":"1980-","publisherPlace":"Oxford ; London [u.a.]"}],"note":["Gesehen am 12.09.2017"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction the EMPEROR-Preserved trial : clinical research : hypertensionEuropean heart journal","id":{"zdb":["2001908-7"],"issn":["1522-9645"],"eki":["320415813"]}}]} | ||
| SRT | |a BOEHMMICHAEMPAGLIFLO7202 | ||